Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH)

Key Inclusion Criteria: One or more of the following: 1. A prior diagnosis of NASH with a Clinical Research Network (CRN) fibrosis score of F1 to F4 based on liver biopsy 2. Evidence of NAFLD by imaging or liver histology as described in the protocol * The possible imaging modalities to assess historic evidence of NAFLD may be based on thresholds as described in the protocol 3. Known high-risk genotype for HSD17B13 (T/T or T/TA) and/or PNPLA3 (C/G,or G/G) 4. A clinical suspicion of NASH based on presence of 2 or more elements of the metabolic syndrome defined by: 1. Waistline that measures \>35 inches (89 centimeters) for women or \>40 inches (102 centimeters) for men 2. Historic fasting triglycerides \>150 mg/dL within the prior 6 months 3. Historic fasting HDL cholesterol \<40 mg/dL in men or \<50 mg/dL in women, or on cholesterol-lowering medication within the prior 6 months 4. Historic fasting blood glucose \>100 mg/dL or on diabetes medication within the prior 6 months 5. Historic blood pressure \>130/85 mmHg, or on anti-hypertensive medication within the prior 6 months Key Exclusion Criteria: 1. Known history or clinical evidence of drug abuse, within the 12 months before screening. Drug abuse is defined as compulsive, repetitive, and/or chronic use of drugs or other substances with problems related to their use and/or where stopping or a reduction in dose will lead to withdrawal symptoms. 2. Excessive alcohol intake for ≥3 months during the past year prior to screening (\>3 units/day for males and \>2 units/day for females is generally considered excessive (unit: 1 glass of wine \[approximately 125 mL\]=1 measure of spirits \[approximately 1 fluid ounce\]=½ pint of beer \[approximately 284 mL\]). 3. History of liver transplant, current placement on a liver transplant list, or Model for End-stage Liver Disease (MELD) score \>12. 4. History of viral and resolved hepatitis or human immunodeficiency virus (HIV). 5. Any malignancy within the past 5 years except for basal cell or squamous epithelial cell carcinoma of the skin, or any carcinoma in situ. Note: Other protocol-defined Inclusion/ Exclusion Criteria apply